<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03065179</url>
  </required_header>
  <id_info>
    <org_study_id>STU 072016-044</org_study_id>
    <nct_id>NCT03065179</nct_id>
  </id_info>
  <brief_title>SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients</brief_title>
  <acronym>RADVAX</acronym>
  <official_title>Phase II Trial of Stereotactic Body Radiation Therapy in Combination With Nivolumab Plus Ipilimumab in Patients With Metastatic Renal Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-institution, single-arm phase II study to determine the safety and efficacy&#xD;
      of SBRT (up to 2 metastatic sites preferentially lung, mediastinum or bone in combination of&#xD;
      nivolumab and ipilimumab in patients with metastatic renal cell carcinoma(with a clear-cell&#xD;
      component and at least 1 measurable metastatic lesion that is not being irradiated).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is planned based on a two-stage design that allows early termination for lack of&#xD;
      efficacy. A safety run-in phase will be included comprising the first 6 patients at minimum&#xD;
      to ensure that the combination of nivolumab plus ipilimumab and SBRT is safe. Then, the&#xD;
      investigators will determine whether the combination of nivolumab plus ipilimumab and SBRT&#xD;
      yields a clinically compelling antitumor activity measured as objective response rate (ORR),&#xD;
      and evaluate other endpoints including Thrombotic thrombocytopenic purpura (TTP), duration of&#xD;
      response (DOR), progression free survival (PFS), overall survival (OS) and local control of&#xD;
      irradiated sites.&#xD;
&#xD;
      There is no previous experience with SBRT used concurrently with nivolumab and ipilimumab in&#xD;
      this study population. Therefore, to ensure that the combination is safe, the first six&#xD;
      patients will be treated and observed for toxicity for 6 weeks after radiation before&#xD;
      continuing with further accrual. Therefore, six patients will be enrolled at the proposed&#xD;
      dose of nivolumab and ipilimumab in combination with SBRT. If 4 out of the first 6 patients&#xD;
      experience Grade 3/4 toxicity or a lower grade toxicity requiring immune suppressive therapy&#xD;
      during the safety run-in observation period (defined as the first 4-cycles, 12 weeks),&#xD;
      enrollment will cease and the study will be halted until further safety analysis of the&#xD;
      combination regimen can be performed. If less than 4 out of the first 6 patients experience&#xD;
      Grade 3/4 toxicities or require steroids, the investigators will proceed with additional&#xD;
      accrual with this regimen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">November 17, 2020</completion_date>
  <primary_completion_date type="Actual">February 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-related Adverse Events Grade 3 or Higher as Assessed by CTCAE v4.0</measure>
    <time_frame>up to 35 months</time_frame>
    <description>An adverse event (AE) will be assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Needing Corticosteroids</measure>
    <time_frame>up to 35 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 35 months</time_frame>
    <description>The ORR is defined as the number of participants with a BOR of CR (Complete response) or PR (Partial response) divided by the number of treated participants. The BOR (Best overall response) is defined as the best response designation, as determined by the investigator, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of first subsequent anti-cancer therapy including radiotherapy, tumor-directed surgery, or systemic anticancer therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR assessment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Kidney Cancer Metastatic</condition>
  <condition>Kidney Cancer</condition>
  <condition>Kidney Cancer, Stage IV</condition>
  <arm_group>
    <arm_group_label>Nivolumab/Ipilimumab plus SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction Dual Immune Checkpoint Inhibition with nivolumab and ipilimumab plus SBRT to 1-2 metastatic sites, followed by nivolumab monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab/Ipilimumab</intervention_name>
    <description>IV immunotherapy</description>
    <arm_group_label>Nivolumab/Ipilimumab plus SBRT</arm_group_label>
    <other_name>Opdivo</other_name>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>SBRT will be delivered in conjunction with immunotherapy</description>
    <arm_group_label>Nivolumab/Ipilimumab plus SBRT</arm_group_label>
    <other_name>stereotactic radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological confirmation of RCC with a clear-cell component&#xD;
&#xD;
          -  Metastatic (AJCC Stage IV) RCC&#xD;
&#xD;
          -  Prior adjuvant or neoadjuvant therapy for localized or locally advanced RCC is allowed&#xD;
             provided recurrence occurred = or &gt; 6 months after the last dose of the adjuvant or&#xD;
             neoadjuvant therapy&#xD;
&#xD;
          -  Any number of prior systemic treatment regimen in the advanced/metastatic setting is&#xD;
             allowed (cytokine, anti-angiogenic, mammalian target of rapamycin (mTOR) inhibitor or&#xD;
             clinical trial) including previously untreated patients&#xD;
&#xD;
          -  Karnofsky Performance Status (KPS) of at least 70%&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  At least 2 metastatic sites of which at least 1 must be measurable as per RECIST 1.1&#xD;
&#xD;
          -  Archival Formalin-fixed paraffin-embedded (FFPE) tumor tissue must be available for&#xD;
             correlative studies (Note: Fine Needle Aspiration (FNA) and bone metastases samples&#xD;
             are not acceptable for submission)&#xD;
&#xD;
          -  Patients with favorable, intermediate and poor risk categories will be eligible for&#xD;
             the study. Patients must be categorized according to favorable versus&#xD;
             intermediate/poor risk status at registration. International Metastatic RCC Database&#xD;
             Consortium (IMDC) must be used to determine prognostic factors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with previously treated brain or CNS (Central nervous system) metastases are&#xD;
             eligible provided that the subject has recovered from any acute effects of&#xD;
             radiotherapy and is not requiring steroids, and any whole brain radiation therapy was&#xD;
             completed at least 4 weeks prior to study drug administration, or any stereotactic&#xD;
             radiosurgery was completed at least 2 weeks prior to study drug administration. Liver&#xD;
             metastases will not be included as part of the radiated lesions to be treated.&#xD;
&#xD;
        Medical History and Concurrent Diseases:&#xD;
&#xD;
          -  Prior treatment with an anti-Programmed cell death(PD) -1, anti-PD-L1, anti-PD-L2,&#xD;
             anti-CD137(cluster of differentiation), or anti-CTLA-4 (cytotoxic&#xD;
             T-lymphocyte-associated protein ) antibody, or any other antibody or drug specifically&#xD;
             targeting T-cell co-stimulation or checkpoint pathways. Prior treatment with high dose&#xD;
             interleukin (HD IL)-2 is allowed.&#xD;
&#xD;
          -  Any active or recent history of a known or suspected autoimmune disease or recent&#xD;
             history of a syndrome that required systemic corticosteroids (&gt; 10 mg daily prednisone&#xD;
             equivalent) or immunosuppressive medications except for syndromes which would not be&#xD;
             expected to recur in the absence of an external trigger. Subjects with vitiligo or&#xD;
             type I diabetes mellitus or residual hypothyroidism due to autoimmune thyroiditis only&#xD;
             requiring hormone replacement are permitted to enroll. Patients with psoriasis not&#xD;
             requiring active, systemic treatment are allowed.&#xD;
&#xD;
          -  Any condition requiring systemic treatment with corticosteroids (&gt; 10 mg daily&#xD;
             prednisone equivalents) or other immunosuppressive medications within 14 days prior to&#xD;
             first dose of study drug. Inhaled steroids and adrenal replacement steroid doses up to&#xD;
             10 mg daily prednisone equivalents are permitted in the absence of active autoimmune&#xD;
             disease&#xD;
&#xD;
          -  Uncontrolled adrenal insufficiency&#xD;
&#xD;
          -  Requirement for anti-coagulation with Coumadin, low molecular weight heparin and&#xD;
             anti-thrombin inhibitors will be accepted if anticoagulation has been stable for at&#xD;
             least 4 weeks and no recent history of prior bleeding complications.&#xD;
&#xD;
          -  Prior malignancy active within the previous 3 years except for locally curable cancers&#xD;
             that have been apparently cured such as basal or squamous cell skin cancer,&#xD;
             superficial bladder cancer, or carcinoma in situ of the cervix, breast or low risk&#xD;
             Gleason 6 prostate cancer&#xD;
&#xD;
          -  Known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome (AIDS)&#xD;
&#xD;
          -  Any positive test for hepatitis B or hepatitis C virus indicating acute or chronic&#xD;
             infection&#xD;
&#xD;
          -  Known medical condition (eg, a condition associated with diarrhea or acute&#xD;
             diverticulitis) that, in the investigator's opinion, would increase the risk&#xD;
             associated with study participation or study drug administration or interfere with the&#xD;
             interpretation of safety results&#xD;
&#xD;
          -  Major surgery (eg, nephrectomy) less than 28 days prior to the first dose of study&#xD;
             drug&#xD;
&#xD;
          -  Anti-cancer therapy less than 14 days prior to the first dose of study drug or&#xD;
             palliative, focal radiation therapy less than 14 days prior to the first dose of study&#xD;
             drug&#xD;
&#xD;
          -  Presence of any toxicities attributed to prior anti-cancer therapy, other than&#xD;
             alopecia, that have not resolved to Grade 1 (NCI CTCAE v4) or baseline before&#xD;
             administration of study drug&#xD;
&#xD;
        Physical and Laboratory Test Findings:&#xD;
&#xD;
          -  Any of the following laboratory test findings:&#xD;
&#xD;
               -  White blood cell (WBC) &lt; 2,000/mm3&#xD;
&#xD;
               -  Neutrophils &lt; 1,500/mm3&#xD;
&#xD;
               -  Platelets &lt; 100,000/mm3&#xD;
&#xD;
               -  aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 3 x ULN (&gt; 5&#xD;
                  x ULN if liver metastases are present)&#xD;
&#xD;
               -  Total Bilirubin &gt; 1.5 x ULN (except subjects with Gilbert Syndrome, who can have&#xD;
                  total bilirubin &lt; 3.0 mg/dL)&#xD;
&#xD;
               -  Serum creatinine &gt; 1.5 x upper limit of normal (ULN) or creatinine clearance &lt; 40&#xD;
                  mL/min (measured or calculated by Cockroft-Gault formula)&#xD;
&#xD;
        Allergies and Adverse Drug Reaction:&#xD;
&#xD;
          -  History of severe hypersensitivity reaction to any monoclonal antibody or study drug&#xD;
             components&#xD;
&#xD;
        Other Exclusion Criteria:&#xD;
&#xD;
          -  Prisoners or subject who are involuntarily incarcerated&#xD;
&#xD;
          -  Not suitable for SBRT treatment&#xD;
&#xD;
          -  Subjects who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Hammers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2017</study_first_posted>
  <results_first_submitted>December 28, 2020</results_first_submitted>
  <results_first_submitted_qc>March 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2021</results_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Hans Hammers</investigator_full_name>
    <investigator_title>Associate Professor, Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 27, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT03065179/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 4 participants who signed the informed consent and went through the screening process as part of the protocol and were screen failures.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Nivolumab/Ipilimumab Plus SBRT</title>
          <description>Induction Dual Immune Checkpoint Inhibition with nivolumab and ipilimumab plus SBRT to 1-2 metastatic sites, followed by nivolumab monotherapy&#xD;
Nivolumab/Ipilimumab: IV immunotherapy&#xD;
SBRT: SBRT will be delivered in conjunction with immunotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nivolumab/Ipilimumab Plus SBRT</title>
          <description>Induction Dual Immune Checkpoint Inhibition with nivolumab and ipilimumab plus SBRT to 1-2 metastatic sites, followed by nivolumab monotherapy&#xD;
Nivolumab/Ipilimumab: IV immunotherapy&#xD;
SBRT: SBRT will be delivered in conjunction with immunotherapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="35" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-related Adverse Events Grade 3 or Higher as Assessed by CTCAE v4.0</title>
        <description>An adverse event (AE) will be assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</description>
        <time_frame>up to 35 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nivolumab/Ipilimumab Plus SBRT</title>
            <description>Induction Dual Immune Checkpoint Inhibition with nivolumab and ipilimumab plus SBRT to 1-2 metastatic sites, followed by nivolumab monotherapy&#xD;
Nivolumab/Ipilimumab: IV immunotherapy&#xD;
SBRT: SBRT will be delivered in conjunction with immunotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-related Adverse Events Grade 3 or Higher as Assessed by CTCAE v4.0</title>
          <description>An adverse event (AE) will be assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Needing Corticosteroids</title>
        <time_frame>up to 35 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nivolumab/Ipilimumab Plus SBRT</title>
            <description>Induction Dual Immune Checkpoint Inhibition with nivolumab and ipilimumab plus SBRT to 1-2 metastatic sites, followed by nivolumab monotherapy&#xD;
Nivolumab/Ipilimumab: IV immunotherapy&#xD;
SBRT: SBRT will be delivered in conjunction with immunotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Needing Corticosteroids</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>The ORR is defined as the number of participants with a BOR of CR (Complete response) or PR (Partial response) divided by the number of treated participants. The BOR (Best overall response) is defined as the best response designation, as determined by the investigator, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of first subsequent anti-cancer therapy including radiotherapy, tumor-directed surgery, or systemic anticancer therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR assessment</description>
        <time_frame>up to 35 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nivolumab/Ipilimumab Plus SBRT</title>
            <description>Induction Dual Immune Checkpoint Inhibition with nivolumab and ipilimumab plus SBRT to 1-2 metastatic sites, followed by nivolumab monotherapy&#xD;
Nivolumab/Ipilimumab: IV immunotherapy&#xD;
SBRT: SBRT will be delivered in conjunction with immunotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>The ORR is defined as the number of participants with a BOR of CR (Complete response) or PR (Partial response) divided by the number of treated participants. The BOR (Best overall response) is defined as the best response designation, as determined by the investigator, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of first subsequent anti-cancer therapy including radiotherapy, tumor-directed surgery, or systemic anticancer therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR assessment</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="38.7" upper_limit="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 35 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nivolumab/Ipilimumab Plus SBRT</title>
          <description>Induction Dual Immune Checkpoint Inhibition with nivolumab and ipilimumab plus SBRT to 1-2 metastatic sites, followed by nivolumab monotherapy&#xD;
Nivolumab/Ipilimumab: IV immunotherapy&#xD;
SBRT: SBRT will be delivered in conjunction with immunotherapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>ALT (Alanine Transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>AST (Aspartate transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Adrenal Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Radiation Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hans Hammers</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>214/645-7445</phone>
      <email>Hans.Hammers@UTSouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

